Immediate Impact
2 by Nobel laureates 54 standout
Citing Papers
Tumor biomarkers for diagnosis, prognosis and targeted therapy
2024 Standout
Theranostic Fluorescent Probes
2024 Standout
Works of R. Cereda being referenced
Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors
2014
First-in-man study of E-3810, a novel VEGFR and FGFR inhibitor, in patients with advanced solid tumors.
2011
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| R. Cereda | 190 | 147 | 92 | 99 | 15 | 460 | |
| Sawsan Sader | 259 | 117 | 87 | 43 | 16 | 496 | |
| Numa R. Gottardi-Littell | 233 | 62 | 194 | 72 | 15 | 493 | |
| Saundra Motley | 119 | 39 | 57 | 62 | 18 | 490 | |
| Zhiwei Zhou | 123 | 27 | 77 | 124 | 22 | 542 | |
| Ornella Pellerito | 210 | 44 | 98 | 58 | 19 | 492 | |
| Eun Kyoung Yang | 222 | 81 | 45 | 90 | 18 | 447 | |
| Ann Chernosky | 109 | 67 | 94 | 137 | 13 | 467 | |
| Yue-Xia Jia | 233 | 211 | 113 | 33 | 12 | 416 | |
| Robert H. Denlinger | 222 | 45 | 31 | 127 | 15 | 508 | |
| Tatsuya Usui | 327 | 50 | 23 | 108 | 19 | 492 |
All Works
Loading papers...